Travel specialist Jules Maury of Scott Dunn Private and Gray & Co.’s Cari Gray chime in on the little luxuries.

Apogee Therapeutics fell by 17.32 percent on Monday to end at $39.24 apiece as investors disposed of positions amid the broader market pessimism, shunning positive results from the company’s ...

Apogee Therapeutics said its antibody treatment alleviated signs and symptoms of atopic dermatitis far more than a placebo — achieving the efficacy goals of a clinical trial.

Apogee Therapeutics’ anti-IL-13 antibody has been tied to a 71% reduction in eczema severity after 16 weeks, hitting the main goal of a phase 2 trial.

Apogee Therapeutics (NASDAQ:APGE) stock drops despite mid-stage trial success for APG777 in treating atopic dermatitis. Read more here.

Apogee shares have spiked on data showing strong efficacy with its atopic dermatitis drug and the potential for dosing just two to four times a year.

By Adriano Marchese Apogee Therapeutics shares soared in premarket trading Monday after the company said it received positive trial data for its atopic dermatitis treatment.

APEX Part A met all primary and key secondary endpoints and exceeded trial objectives, including 71.0% decrease from baseline in EASI at Week 16 APG777 demonstrated EASI-75 of 66.9% (42.5% placebo ...

Apogee Therapeutics, Inc.’s APG777 shows best-in-class week-16 efficacy and quarterly/semi-annual dosing potential. In my view, this could give this drug candidate a great competitive profile ...

Apogee Therapeutics will announce Phase 2 APEX trial data for APG777 on July 7, 2025, with a follow-up conference call.

Investing.com -- Apogee (NASDAQ: APOG) Therapeutics, Inc. (NASDAQ: APGE) stock surged 24% on Monday after the clinical-stage biotechnology company announced positive 16-week data from its Phase 2 ...